現職

• 林口長庚風濕過敏免疫科主治醫師
   

學歷

• 長庚大學醫學系
   

經歷

• 財團法人長庚紀念醫院林口分院風濕過敏免疫科主治醫師

• 財團法人長庚紀念醫院林口分院風濕過敏免疫科總醫師

• 財團法人長庚紀念醫院林口分院內科部住院醫師
   

學會與認證

• 中華民國醫用超音波學會

• 中華民國免疫醫學會

• 中華民國風濕病醫學會

• 台灣內科醫學會

• Internal medicine, 2012 (No.9668) 內專醫字第9668號

• Practice license number (No. 045602) 醫字第045602 號  

• Rheumaology, 2014(No.360)中僂專醫字第360號

• Clinical immunology, 2015 (No. 635) 中免專醫字第635號

• 中超專常證字第eRI000041號
   

論文及期刊發表​

• Tien-Ming Chan, Chuan Lee, Chang-Fu Kuo, Huei-Huang Ho, Lieh-Bang Liou, Ji-Yih Chen, Shue-Fen Luo, Kuang-Hui Yu Use of Serum Level of Immunoglobulin G4 in the Differential Diagnosis of Autoimmune Pancreatitis and Pancreatic Cancer Formosan Journal of Rheumatology Vol.28, No.1, September, 2014, p18~26

• Yu, Kuang-Hui MD; Chan, Tien-Ming MD; Tsai, Ping-Han MD; Chen, Ching-Hui BS; Chang, Pi-Yueh MS Diagnostic Performance of Serum IgG4 Levels in Patients With IgG4-Related Disease Medicine: Medicine . 94(41):e1707, October 2015.

• Tien-Ming Chan, Shue-Fen Luo, Kuang-Hui Yu, Lai-Chu See,Lu-Hsiang Huang, Chang-Fu Kuo, Risk of Cancer in Patients with Ankylosing Spondylitis: A Nationwide Cohort Study in Taiwan. Scandinavian Journal of Rheumatology.2020(in press) 

• Tien-Ming Chan , Meng-Jiun Chiou , Chang-Fu Kuo Adverse pregnancy outcomes in women with Behçet's disease: population-based registry linkage study in Taiwan Clinical Rheumatology 2021,epub
   

Clinical trials involved
Co-Investigator

• A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab. (IRB: 101-4192A)

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis. (IRB: 101-2659A)

• Real world effectiveness of abatacept in rheumatoid arthritis patients: a prospective, single-arm, multi-center observational study in Taiwan. (IRB: 103-0668B)

• A Phase 3b/4 Randomized Safety Endpoint Study of 2 Doses of Tofacitinib in Comparison to a TNF Inhibitor in Subjects with Rheumatoid Arthritis. (IRB: 103-0541A)

• A Phase 3b/4 Randomized Double Blind Study Of 5 mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis. (IRB: 103-3644A)

• A randomized, controlled double-blind study comparing the efficacy and safety of voclosporin (23.7 mg BID, or 39.5 mg BID) with placebo in achieving remission in patients with active lupus nephritis. (IRB: 103-3651A)

• A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BMS-931699 vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects with Active Systemic Lupus Erythematosus. (IRB: 104-0170A2)

• A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects with Active Systemic Lupus Erythematosus. (IRB: 104-2451A)

• A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Refractory Subjects With Active Radiographic Axial Spondyloarthritis. (IRB: 104-5085A)

• A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Nonradiographic Axial Spondyloarthritis. (IRB: 104-5091A )

• A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Subjects With Active Radiographic Axial Spondyloarthritis. (IRB: 104-5194A)

• A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study

• Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult  Subjects with Active Systemic Lupus Erythematosus. (IRB: 104-5465A)

• A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis. (IRB: 104-8738A2)

• A phase II multicenter, randomized, double-blind, placebo-controlled, dose-range finding study to evaluate the safety and efficacy of ALX-0061 administered subcutaneously in subjects with moderate to severe active Systemic Lupus Erythematosus. (IRB: 104-6673A2)

• A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults with Early Rheumatoid Arthritis who are Methotrexate Naïve. (IRB: 104-5743A2)

• A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs. (IRB: 104-8786A)

• A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR). (IRB: 104-8794A)

• A Randomized, Double-Blind, Placebo-Controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients with Rheumatoid Arthritis (RA) who Had an Inadequate Response to DMARDs. (IRB: 104-4061A)

• Open-Label Extension Study in Rheumatoid Arthritis Patients Who Have Completed Phase IIb Study or Phase III Study of ASP015K. (IRB: 201600970A0)

• A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate. (IRB: 201601219A0)

• A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks alone and in Combination with Methotrexate (MTX) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are Naïve to MTX Therapy. (IRB: 201601381A0)

• A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations. (IRB: 201601653A4)

• A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS. (IRB: 201700201A4)

• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study with an Open Label Extension to Evaluate the Efficacy and Safety of KHK4827 in Subject with Axial Spondyloarthritis. (IRB: 201700627A4)

• A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis. (IRB: 201700720A4)

• A Multicenter, Double-blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis. (IRB: 201701566A4)

• A PHASE II, OPEN-LABEL EXTENSION STUDY OF PATIENTS PREVIOUSLY ENROLLED IN STUDY GA30044 TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS. (IRB: 201701913A4)

• A Multicenter, Randomized, Double-blind, Placebo controlled, Parallel-group Study of Ustekinumab in Subjects with Active Systemic Lupus Erythematosus. (IRB: 201800706A0)

• MIRACLE (Methotrexate inadequate response patient with Rheumatoid Arthritis treated by Adalimumab in combination with Low-dose Methotrexate) Study. (IRB: 201801103A4)

• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE). (IRB: 201801726A4)

• A phase 2 study to investigate the safety and efficacy of ABBV-105 and Upadacitinib given alone or in combination(ABBV-599 combination) in subjects with moderately to severely active systemic lupus erythematosus (201901109A4)

• A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)(201901222A4)

• A real-world, prospective, observational study to investigate the clinical responses in ankylosing spondylitis patients on adalimumab therapy in Taiwan (EAST)